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PURPOSE. Docosahexaenoic acid (DHA) continues to be evaluated and recommended as
treatment and prophylaxis for various diseases. We recently assessed efficacy of high-dose
DHA supplementation to slow vision loss in patients with X-linked retinitis pigmentosa
(XLRP) in a randomized clinical trial. Because DHA is a highly unsaturated fatty acid, it could
serve as a target for free-radical induced oxidation, resulting in increased oxidative stress.
Biosafety was monitored during the 4-year trial to determine whether DHA supplementation
was associated with identifiable risks.
METHODS. Males (n ¼ 78; 7–31 years) meeting entry criteria were enrolled. The modified
intent-to-treat cohort (DHA ¼ 33; placebo ¼ 27) adhered to the protocol ‡ 1 year.
Participants were randomized to an oral dose of 30 mg/kg/d DHA or placebo plus a daily
multivitamin. Comprehensive metabolic analyses were assessed for group differences.
Treatment-emergent adverse events including blood chemistry metabolites were recorded.
RESULTS. By year 4, supplementation elevated plasma and red blood cell–DHA 4.4- and 3.6-fold,
respectively, compared with the placebo group (P < 0.00001). Over the trial duration, no
significant differences between DHA and placebo groups were found for vitamin A, vitamin E,
platelet aggregation, antioxidant activity, lipoprotein cholesterol, or oxidized LDL levels (all
P > 0.14). Adverse events were transient and not considered severe (e.g., gastrointestinal [GI]
irritability, blood chemistry alterations). One participant was unable to tolerate persistent GI
discomfort.
CONCLUSIONS. Long-term, high-dose DHA supplementation to patients with XLRP was
associated with limited safety risks in this 4-year trial. Nevertheless, GI symptoms should
be monitored in all patients taking high dose DHA especially those with personal or family
history of GI disturbances. (ClinicalTrials.gov number, NCT00100230.)
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Retinitis pigmentosa (RP) is a retinal degenerative diseasecharacterized by night blindness and visual field constric-
tion1 with four underlying inheritance patterns. The X-linked
form of RP (XLRP) is among the most severe with night
blindness often detectable by age 5 years2–4 and legal blindness
by the second or third decade. Gene defects are known to
cause retinal degeneration, yet factors such as environment,
diet, stress, and/or metabolism may modify disease severity.
Many patients with RP have lower plasma and red blood cell
(RBC) levels of the n3 polyunsaturated fatty acid docosahex-
aenoic acid (DHA; 22:6n3) than normally-sighted controls.5
Blood DHA was significantly correlated with age-adjusted ERG
responses in XLRP such that patients with lower RBC-DHA
tended to have lower ERG amplitudes.6 These findings were
similarly documented in approximately 70% of female XLRP
carriers (Hoffman DR, et al. IOVS 1998;39:ARVO Abstract 725).
A reduction in DHA biosynthesis was demonstrated in XLRP
using stable isotopes to assess in vivo metabolism7 suggesting
that downregulation of hepatic D5 desaturase may contribute to
subnormal blood DHA levels. Thus, daily supplementation with
DHA may bypass any decrease in DHA biosynthesis.
Docosahexaenoic acid comprises 1% to 5% of membrane
fatty acids in most human tissues; however, it is the most
abundant fatty acid in the retina.8 This n3 fatty acid can
increase membrane fluidity and modify the mobility of vital
proteins and activities of retinal enzymes,9,10 promote
photoreceptor differentiation,11 and antiapoptotic activity.12
The highly unsaturated nature of DHA makes it a potential
target for free radical oxidative damage. Increased polyunsat-
urated fatty acid (PUFA) intake, particularly long-chain PUFAs
(LCPUFAs; >18 carbons), may lead to elevated oxidative
stress and subsequent membrane damage.13,14 The n3
LCPUFAs demonstrate metabolic competition with arachi-
donic acid (ARA; 20:4n6) leading to alterations in prostaglan-
dins and leukotrienes and reportedly diminish platelet
aggregation and increase bleeding times.15 Numerous n3-
supplementation studies report elevations in low- and high-
density lipoprotein (LDL and HDL)-cholesterol,16 and high
doses of DHA and eicosapentaenoic acid (EPA; 20:5 n3)
Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
www.iovs.org j ISSN: 1552-5783 4958
Downloaded from iovs.arvojournals.org on 06/29/2019
derived from fish oil have been utilized to decrease plasma
triacylglycerols.17
Long-term clinical trials with XLRP18 or RP19,20 patients
receiving DHA doses ranging from 400 mg/d21 to 1200
mg/d22 have reported minimal safety risks. The current DHAX
trial23 employed DHA doses based on bodyweight resulting in
intakes up to 3600 mg/d. The 30 mg/kg/d DHAX dose is within
the range (3–84 mg DHA/kg/d) received by nursing infants24–26
and less than the 50–100 mg/kg/d doses used in three recent
clinical trials.27–29 The DHAX trial provides the opportunity to
assess the biological safety and metabolic consequences of




Seventy-eight males diagnosed with XLRP (ages 7–31 years)
were randomized to DHA (n ¼ 41) or placebo (n ¼ 37)
supplements for a 4-year duration; DHAX recruitment and
eligibility criteria were described previously.23 Sixteen non-
adherent participants dropped from the study during year 1,
two additional participants were determined genetically to
be non-XLRP. The resulting modified intent-to-treat (mITT)
cohort consisted of 60 participants (33 DHA; 27 placebo)
that completed ‡1 year. Subsequently, eight participants
(three DHA; five placebo) dropped before year 4, primarily
due to apathy and/or continued vision loss.
Informed consent was obtained from participants and/or
parents of minors. Research adhered to the tenets of the
Declaration of Helsinki and was approved by the Institutional
Review Board of The University of Texas Southwestern Medical
Center at Dallas. Study oversight was conducted by a Data and
Safety Monitoring Committee (see Acknowledgments).
Age-matched, healthy males (n¼29) with normal acuity and
visual fields were recruited to provide blood samples for
normative biochemistry measures.
Trial Design
A computer-generated, varied block size, randomization
schedule was stratified by age and vitamin A supplementation.
Visual function, blood samples, and bodyweight were assessed
at baseline and annually (Supplementary Table S1). Individu-
alized daily capsule intakes to achieve DHAX dosage were
adjusted annually. Treatment-emergent adverse events (TEAE),
including self-reported and blood analysis-derived events, were
recorded.
Intervention
Gelatin capsules contained DHA-enriched (DHASCO) or corn/
soy oil (placebo) triglycerides (DSM Nutritional Products,
Columbia, MD, USA). The DHA content of DHASCO capsules
provided 200 mg DHA in each 500 mg capsule. Fatty acid
profiles of capsules are given in Supplementary Table S2. Study
capsules were indistinguishable from placebo in appearance,
smell, or taste and contained small amounts of vitamins E and C
as antioxidants and a food-grade orange extract as flavoring.
Toxicological outcomes of DHASCO consumption were
considered minor and not of clinical significance.30
Initial bodyweights were between 22 and 123 kg. At 30
mg/kg, the corresponding capsule intake ranged from 3 to 18
capsules/d providing a total DHA dose of 600 to 3600
mg/d. The corresponding total amount of fat (oil) ranged from
1.5 to 9 g/d and is comparable to 1/2 to 2 pats of butter.
Commercial multivitamins were provided to all participants
to maintain a minimum antioxidant status. An over-the-counter
multivitamin (CVS ‘‘Daily Multiple Essential,’’ SKU: 41656; CVS
Corp., Lowell, MA, USA) provided 100% of the recommended
daily amounts of vitamins A, C, D, E, B6, and B12.
Compliance
Capsule counts were conducted annually to assess protocol
adherence. Docosahexaenoic acid in RBCs provided a more
precise compliance measure; however, during the trial this
information was only available to the monitoring committee.
Capsule use was followed with a self-report diary completed
every 3 months by the adult participant or with parental
assistance in children.
Blood Samples
Fasting blood samples were drawn from an antecubital vein at
baseline, 6 months, and annual visits; a total of 14.3 mL per
blood draw was collected. Plasma and RBC fatty acids were
assessed every 6 months and biosafety assays conducted
annually. Antioxidant defense mechanisms were indexed by
plasma concentrations of: the antioxidant vitamin E; the retinal
chromophore precursor, vitamin A; oxidized low density
lipoprotein (oxLDL), and a total plasma antioxidant capacity
analysis. Whole blood platelet aggregation was monitored to
address concerns of increased bleeding due to inactivation of
platelet activation responses. A comprehensive blood panel
assessed metabolic modifications and lipoprotein lipids were
also measured.
Fatty Acid Analysis
Fatty acids were analyzed using previously detailed methodol-
ogy.31 Plasma and RBCs were separated by centrifugation,
lipids were solvent extracted, total lipids transmethylated, and
methyl esters quantified by capillary column gas chromatog-
raphy with flame ionization detection. Upon trial conclusion,
fatty acids from placebo and DHASCO capsules were similarly
analyzed. Fatty acid content was expressed as relative weight
percentage of total fatty acids.
Biosafety Analysis
Vitamin A (retinol) and vitamin E (a-tocopherol) were
quantified by C18 reverse-phase high-pressure liquid chroma-
tography following lipid-soluble vitamin extraction.32 Retinol
and a-tocopherol concentrations were expressed as lM.
Total antioxidant capacity of plasma was assessed using the
total peroxyl radical trapping parameter.33 Quenching capacity
of plasma as measured by chemiluminescence was compared
with a standard curve of the synthetic vitamin E derivative,
Trolox. Antioxidant activity was expressed as lM ‘‘Trolox
equivalents.’’
The oxLDL analysis utilized a commercially available ELISA
kit (#10-1143-01; Mercodia AB, Uppsala, Sweden). Normal
plasma levels of oxLDL were reported to range from 25 to 120
U/L.34
Platelet aggregation was measured in citrate-anticoagulated
whole blood using type I collagen as agonist.35 Results are
expressed as impedance (ohms) to aggregation.
Lipoprotein Lipid Profiles
Total cholesterol, HDL-cholesterol, and triacylglycerides (TG)
were measured using assay-specific disposable test cassettes
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and an autoanalyzer. Low-density lipoprotein cholesterol was
calculated using the Friedewald equation.36 Concentrations
were recorded as mg/dL.
Comprehensive Metabolic Panel
Serum was sent to a commercial clinical laboratory
(LabCorp, Dallas, TX, USA) for blood chemistry analysis.
Results were reported compared with age-appropriate
normative ranges and outlying results were flagged. Norma-
tive metabolite values and cutoff thresholds are given in
Table 1.
Treatment-Emergent Adverse Events
All related, possibly related, or unrelated adverse events
were recorded. Only TEAEs judged to be related or possibly
related were analyzed. Treatment-emergent adverse events
were self-reported at annual visits as well as in quarterly
diaries. Blood chemistry anomalies were identified by
Division of AIDS (DAIDS37) criteria. Serious adverse events
requiring hospitalization were to be reported immediately to
study investigators.
Statistical Analysis
All mITT data for the 4-year trial were used for analysis. Two-
tailed t-tests were used to compare study groups at baseline
and for comparing overall change attributable to intervention
(i.e., year 4 minus year 0 data). Values are given as mean 6 SE.
Statistical software (SPSS version 22; IBM Corporation,
Armonk, NY, USA; and Statistica version 12; StatSoft, Inc.,
Tulsa, OK, USA) were used for statistical analyses.
RESULTS
Baseline Demographics, Anthropometry, and
Blood Chemistry
Demographic, anthropometric, and blood chemistry measures
were similar between groups at baseline (Supplementary Table
S3). The DHA-supplemented group was slightly older (mean¼
16.1 vs. 14.9 years), had marginally higher plasma-DHA (1.57
vs. 1.47%), RBC-DHA (3.12% vs. 2.86%), and plasma total
cholesterol (168.3 vs. 151.7 mg/dL) compared with placebo.
The 18 participants who dropped from the study were no
different according to demographics, anthropometrics, and












Plasma DHA, % 1.42 6 0.10* 0.11 6 0.07 (1.33 6 0.08) 4.16 6 0.29 (5.79 6 0.29) <0.00005
Plasma ARA, % 9.60 6 0.28* 0.20 6 0.31 (8.16 6 0.08) 2.89 6 0.32 (6.14 6 0.05) <0.00005
RBC DHA, % 2.91 6 0.14* 0.04 6 0.13 (2.82 6 0.03) 6.78 6 0.51 (9.97 6 0.09) <0.00005
RBC ARA, % 16.8 6 0.40* 0.43 6 0.21 (15.8 6 0.06) 4.25 6 0.39 (12.1 6 0.07) <0.00005
Plasma antioxidant activity, mM TEq 279 6 17* 20.9 6 15.1 (308 6 17) 40.2 6 12.5 (316 6 15) 0.33
Plasma oxidized LDL, U/L 54 6 2* 7.60 6 2.75 (45.9 6 2.3) 2.19 6 1.61 (50.3 6 1.8) 0.08
Plasma vitamin A, lM 3.33 6 0.15* 0.37 6 0.11 (3.23 6 0.12) 0.54 6 0.16 (3.71 6 0.16) 0.45
Plasma vitamin E, lM 26.1 6 1.6* 6.79 6 2.00 (28.4 6 1.4) 8.24 6 1.56 (32.5 6 1.4) 0.56
Whole blood platelet aggregation, ohms 16 6 6* 2.50 6 0.97 (12.1 6 0.7) 2.80 6 0.74 (11.1 6 0.4) 0.80
Plasma total cholesterol, mg/dL <240† 6.23 6 6.10 (160 6 5) 4.10 6 5.64 (176 6 5) 0.80
Plasma LDL cholesterol, mg/dL <160† 5.39 6 4.60 (92 6 5) 7.19 6 5.46 (109 6 5) 0.83
Plasma HDL cholesterol, mg/dL >23† 2.32 6 2.71 (46 6 3) 1.03 6 3.01 (52 6 3) 0.76
Plasma triacylglycerols, mg/dL <500† 12.0 6 13.7 (118 6 19) 10.8 6 9.2 (85 6 9) 0.16
Glucose, mg/dL <126† 5.95 6 5.44 (97.5 6 5.3) 3.30 6 2.07 (89.3 6 1.4) 0.08
BUN, mg/dL <36† 0.73 6 0.71 (13.3 6 0.7) 0.03 6 0.73 (13.6 6 0.5) 0.51
Creatinine, mg/dL <2.1† 0.07 6 0.02 (0.82 6 0.04) 0.10 6 0.03 (0.84 6 0.03) 0.77
BUN/creatinine ratio <38† 3.23 6 1.22 (16.6 6 0.9) 3.63 6 1.35 (17.0 6 0.8) 0.83
Sodium, mg/dL <151† 0.09 6 0.49 (140.7 6 0.4) 0.07 6 0.64 (140.2 6 0.5) 0.86
Potassium, mg/dL <6.1† 0.04 6 0.10 (4.65 6 0.60) 0.15 6 0.09 (4.69 6 0.08) 0.40
Chloride, mg/dL <153† 0.45 6 0.56 (102.7 6 0.6) 0.57 6 0.52 (102.6 6 0.4) 0.89
Carbon dioxide, mg/dL <45† 0.59 6 0.44 (23.1 6 0.4) 0.50 6 0.54 (23.1 6 0.4) 0.90
Calcium, mg/dL <11.6† 0.17 6 0.08 (9.70 6 0.09) 0.07 6 0.08 (9.85 6 0.05) 0.034
Total protein, mg/dL <12† 0.09 6 0.09 (7.26 6 0.08) 0.08 6 0.07 (7.36 6 0.06) 0.14
Albumin, mg/dL >2.9† 0.02 6 0.05 (4.64 6 0.05) 0.16 6 0.06 (4.76 6 0.04) 0.09
Globulin, mg/dL <6.3† 0.10 6 0.06 (2.62 6 0.06) 0.08 6 0.05 (2.59 6 0.05) 0.75
Albumin/globulin ratio <3.5† 0.07 6 0.04 (1.79 6 0.04) 0.12 6 0.05 (1.87 6 0.05) 0.39
Total bilirubin, mg/dL <1.9† 0.02 6 0.04 (0.41 6 0.06) 0.11 6 0.06 (0.54 6 0.07) 0.09
Alkaline phosphatase, IU/L <1040† 58 6 21 (135 6 20) 33 6 19 (160 6 20) 0.40
SGOT, IU/L <156† 0.77 6 2.66 (24.5 6 2.9) 1.80 6 2.04 (23.7 6 1.7) 0.76
SGPT, IU/L <143† 7.05 6 4.48 (29.6 6 4.7) 4.13 6 5.78 (26.5 6 5.7) 0.71
Significant differences (P < 0.05) in bold. TEq, vitamin E derivative, Trolox equivalents; BUN, blood urea nitrogen; SGOT, serum glutamic-
oxaloacetic transaminase (also AST, aspartate aminotransferase); SGPT, serum glutamic-pyruvic transaminase (also ALT, alanine aminotransferase).
* Normative values (n ¼ 29 age-matched; mean 6 SE).
† Threshold cutoff for moderate AE based on DAIDS criteria.37
DHAX Trial Biosafety IOVS j August 2014 j Vol. 55 j No. 8 j 4960
Downloaded from iovs.arvojournals.org on 06/29/2019
RBC-DHA but on average were slightly older (mean ¼ 19.6
years) than the mITT cohort.
DHA and ARA
Mean plasma DHA levels in mITT participants at baseline were
not significantly different from age-matched normative males
(1.52% 6 0.06% vs. 1.43% 6 0.10%; P ¼ 0.38; Supplementary
Table S4). Red blood cell–DHA at baseline was similar to mean
normal (3.00% 6 0.10% vs. 2.91% 6 0.15%; P ¼ 0.59;
Supplementary Table S5). The placebo group showed little
variation in either plasma (Fig. 1) or RBC (Fig. 2) DHA levels
throughout the trial consistent with protocol recommenda-
tions to abstain from over-the-counter capsules containing
DHA or altering consumption of cold water n3-rich fish.
The DHA group reached a plateau level at 6 months for
plasma DHA that averaged 5.90% 6 0.30% for the remainder of
the trial. Similarly, an average 6-month to 4-year plateau level of
FIGURE 1. Docosahexaenoic acid and ARA levels in plasma lipids as a function of treatment intervention. Mean 6 SE plasma levels of DHA (u, &)
and ARA (n, m) in participants of the high-dose DHA-supplementation arm (filled symbols) or the placebo arm (open symbols), respectively. Gray
dashed lines are average plasma DHA (lower section of plot; 1.42% 6 0.1%) and average plasma ARA (upper section of plot; 9.60% 6 0.27%) from
29 age-matched individuals with normal visual function; grayed area demarks 95% CI (DHA range, 1.22%–1.62%; ARA range, 9.1%–10.1%).
FIGURE 2. Docosahexaenoic acid and ARA levels in RBC lipids as a function of treatment intervention. Mean 6 SE RBC levels of DHA (u, &) and
ARA (n, m) in participants of the high-dose DHA-supplementation arm (filled symbols) or the placebo arm (open symbols), respectively. Gray
dashed lines are average RBC-DHA (lower section of plot; 2.9% 6 0.3%) and average RBC-ARA (upper section of plot; 16.8% 6 0.4%) from 29 age-
matched individuals with normal visual function; grayed area demarks 95% CI (DHA range, 2.3%–3.5%; ARA range, 16.0%–17.6%).
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10.44% 6 0.44% was attained in RBCs. Participants receiving
DHA had mean plasma and RBC-DHA levels 4.4- and 3.6-fold
higher at year 4 than in the placebo group (both P < 0.00001;
Table 1).
Consistent with metabolic competition between n3 and n6
fatty acids, mean plasma ARA levels were reduced 28% in the
first 6 months and remained depressed throughout the trial in
DHA-supplemented participants (Fig. 1). The 6-month to 4-
year average plasma ARA level in the DHA group was 6.27% 6
0.18% compared with 8.07% 6 0.29% in the placebo group.
The plasma ARA level in DHA participants was significantly
reduced compared with both the placebo and normative
groups at year 4 (both P < 0.00001; Table 1). In a similar
manner, the average 6-month to 4-year level of ARA in RBCs
was reduced 24% compared with the placebo group (Fig. 2;
11.8% 6 0.26% vs. 15.5% 6 0.18%, respectively;
P < 0.00001).
The highest plasma and RBC-DHA levels were attained by a
participant at the 6-month interval (10.1% and 14.9%,
respectively). The lowest levels of plasma and RBC-ARA were
3.31% and 8.64% at the 3.5- and 2-year intervals, respectively,
but in different participants. After trial termination and
unmasking, one DHA participant was determined to be
noncompliant throughout most of the trial with an RBC-DHA
level at baseline of 3.3% and 3.4% at year 4.
Other Fatty Acids
Although statistically significant, a 1.7% increase in total
saturated fatty acids in RBCs of the DHA group at trial year 4
is not of clinical significance and contrasts with no increase in
saturates in plasma (Tables 2, 3). Similarly, the significant 10%
increase in total monounsaturated fatty acids in plasma
(P ¼ 0.006) contrasts with no change in monounsaturates in
RBCs. The n3 and n6 essential fatty acids, a-linolenic (a-LNA)
and linoleic acid (LA), respectively, were unchanged by DHA
supplementation. Retroconversion of DHA to EPA was evident
by 1.7- and 1.5-fold increases compared with placebo in plasma
and RBC levels of EPA at year 4. A 40% to 50% reduction in
both plasma and RBC content of n3docosapentaenoic acid
(DPAn3) in DHA-supplemented participants was observed
compared to placebo.
Competition between n3 and n6 fatty acids was most
evident by the significant 70% decreases of the n6 metabolic
end-product, DPAn6 (P < 0.0005) in plasma and RBCs;
similarly, 20:3n6 and 22:4n6 were reduced by DHA supple-
mentation. Over the 4-year interval, total n3 LCPUFAs in
plasma and RBCs were significantly increased by 2- to 3-fold
(P < 0.0005) while total n6 LCPUFAs decreased 30% by DHA
supplementation (P < 0.0005; Tables 2, 3). Total PUFA of the
n3 and n6 series include the essential fatty acids, LA and a-LNA,
and are more reflective of dietary fat intake. Docosahexaenoic
acid supplementation diminished n6 PUFA in plasma lipids by
only 7%, whereas the n6 LCPUFA content was decreased 28%
compared with placebo. Nevertheless, the plasma n6 to n3
TABLE 2. Fatty Acid Profile of mITT Cohort at Year 4 of DHAX Clinical
Trial as Percentage of Total Plasma Lipids*
Placebo DHA P
Valuen ¼ 22 n ¼ 30
n3 fatty acids
a-LNA 0.70 6 0.06 0.66 6 0.04 0.54
EPA 0.41 6 0.05 1.08 6 0.11 <0.0005
DPAn3 0.57 6 0.02 0.36 6 0.02 <0.0005
DHA 1.33 6 0.08 5.79 6 0.29 <0.0005
n6 fatty acids
LA 32.1 6 1.1 32.1 6 0.8 0.98
20:3n6 2.00 6 0.08 1.49 6 0.07 <0.0005
ARA 8.16 6 0.37 6.14 6 0.27 <0.0005
22:4n6 0.37 6 0.02 0.17 6 0.02 <0.0005
DPAn6 0.25 6 0.01 0.07 6 0.01 <0.0005
Totals
Total saturates† 35.3 6 0.7 35.3 6 0.7 0.98
Total
monounsaturates‡ 18.0 6 0.5 16.3 6 0.4 0.016
Total n3 PUFA 3.06 6 0.13 7.94 6 0.38 <0.0005
Total n6 PUFA 43.6 6 4.8 40.4 6 0.8 0.019
Total n3 LCPUFA 2.32 6 0.13 7.26 6 0.37 <0.0005
Total n6 LCPUFA 11.0 6 0.4 8.09 6 0.35 <0.0005
Ratios
DPAn6/DHA ratio 0.189 6 0.012 0.019 6 0.005 <0.0005
n6/n3 PUFA ratio 14.8 6 0.7 5.59 6 0.41 <0.0005
n6/n3 LCPUFA ratio 4.88 6 0.16 1.33 6 0.17 <0.0005
Unsaturation index 141 6 2 156 6 2 <0.0005
Unsaturation index is the sum of (number of double bonds 3
percentage of each fatty acid). Statistical significance determined by t-
test at P < 0.05 and given in bold. DPAn3, docosapentaenoic acid,
22:5n3; DHA, docosahexaenoic acid, 22:6n3; LA, linoleic acid, 18:2n6;
ARA, arachidonic acid, 20:4n6; DPAn6, docosapentaenoic acid, 22:5n6.
* Values are mean 6 SE for relative percentage of total fatty acids in
plasma.
† Includes 14:0, 16:0, 17:0, 18:0, 20:0, 22:0, and 24:0.
‡ Includes 16:1, 18:1, 20:1, 22:1, and 24:1.
TABLE 3. Fatty Acid Profile of mITT Cohort at Year 4 of DHAX Clinical
Trial as Percentage of Total RBC Lipids*
Placebo DHA-Supplemented P
Valuen ¼ 22 n ¼ 30
n3 fatty acids
a-LNA 0.14 6 0.01 0.13 6 0.01 0.29
EPA 0.35 6 0.03 0.85 6 0.08 <0.0005
DPAn3 4.44 6 0.10 1.23 6 0.06 <0.0005
DHA 2.82 6 0.14 9.97 6 0.50 <0.0005
n6 fatty acids
LA 13.3 6 0.28 12.7 6 0.20 0.07
20:3n6 1.85 6 0.07 1.46 6 0.04 <0.0005
ARA 15.8 6 0.3 12.1 6 0.39 <0.0005
22:4n6 4.44 6 0.10 2.20 6 0.15 <0.0005
DPAn6 0.79 6 0.03 0.26 6 0.04 <0.0005
Totals
Total saturates† 41.4 6 0.17 42.1 6 0.16 0.002
Total
monounsaturates‡ 16.5 6 0.32 16.6 6 0.14 0.79
Total n3 PUFA 5.50 6 0.19 12.23 6 0.52 <0.0005
Total n6 PUFA 36.6 6 0.31 29.0 6 0.51 <0.0005
Total n3 LCPUFA 5.33 6 0.19 12.07 6 0.52 <0.0005
Total n6 LCPUFA 23.3 6 0.30 16.3 6 0.6 <0.0005
Ratios
DPAn6/DHA ratio 0.294 6 0.016 0.038 6 0.009 <0.0005
N6/N3 PUFA ratio 6.83 6 0.26 2.61 6 0.20 <0.0005
n6/n3 LCPUFA ratio 4.47 6 0.16 1.53 6 0.15 <0.0005
Unsaturation index 165 6 1 176 6 1 <0.0005
Statistical significance determined by t-test at P < 0.05 and given in
bold.
* Values are mean 6 SE for relative percentage of total fatty acids in
red blood cells.
† Includes 14:0, 16:0, 17:0, 18:0, 20:0, 22:0, and 24:0.
‡ Includes 16:1, 18:1, 20:1, 22:1, and 24:1.
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PUFA ratio was decreased 62% in DHA participants compared
with placebo; 5.6 vs. 14.8 (Table 2). In RBCs, total n6 PUFAs
were reduced 21% and the n6-to-n3 PUFA ratio was diminished
62% by DHA-supplementation compared with placebo; 2.6 vs.
6.8 (Table 3). The unsaturation indices (number of double
bonds 3 percentage of each fatty acid) in plasma and RBC were
significantly elevated in DHA-supplemented participants (P <
0.0005) by year 4.
Treatment-Related Changes in Biosafety Measures
Despite marked elevations in plasma and RBC-DHA levels and
reductions in ARA levels (P < 0.00005; Table 1), no group
differences over the 4-year trial were found for anthropomet-
rics, platelet aggregation, plasma antioxidant status, oxLDL or
vitamins A and E (P > 0.08). Significant differences from
placebo were found for DHA-supplemented participants for
blood calcium (P ¼ 0.034); however, this was judged not of
clinical relevance as plasma levels were within the normal
range (<11.6 mg/dL; Table 1). No other blood elements
differed between groups (P > 0.05). No group differences
were evident for lipoproteins including total (P¼0.80), LDL- (P
¼ 0.99), or HDL-cholesterol (P ¼ 0.76). Although DHA
supplementation decreased TG content over the 4-year trial,
this was not statistically significant (P¼ 0.16). An effect of age
on biochemistry outcomes was not evident; divided by median
age there were no differences in the year 0 to year 4 change
values between the younger (14 years) and older (>14 years)
placebo and DHA-supplemented groups for any of the above
safety measures (data not shown).
Treatment-Emergent Adverse Events
Eighteen individuals dropped before completing year 1; three
of these individuals reported one TEAE each: gastrointestinal
(GI) upset, dehydration, and visual disturbance (i.e., loss of
vision, increased floaters, and light sensitivity). Among the
mITT cohort, 23 individuals had a total of 39 TEAEs (Table 4).
Nineteen TEAEs were self-reported (13 DHA, 6 placebo).
Twenty TEAEs were identified by blood chemistry (7 DHA, 13
placebo). Two self-reported TEAEs in the placebo group and
one in DHA group were considered related to intervention as
abstinence from capsules alleviated symptoms. The latter
experienced GI symptoms sporadically for 2 years (three AE
reports) including diarrhea, flatulence, and eructation; symp-
toms were alleviated by capsule discontinuation. This partic-
ipant dropped at year 2 as it was determined he had a family
history of inflammatory bowel disease (Crohn). No serious
TEAEs requiring hospitalization were reported. Further TEAE
details are given in the Supplementary Results.
Overall, TEAEs were minor and sporadic in occurrence and
duration, except one participant with recurrent GI symptoms.
No trends were identified in self-reported TEAEs or blood
chemistry.
DISCUSSION
Supplementation of DHA at 30 mg/kg/d resulted in 4.4- and
3.6-fold increases in mean plasma and RBC DHA levels within
6 months and remained similarly elevated throughout the trial.
Mean plasma and RBC DHA levels attained over the 4 years
were 5.9% and 10.4% with individual maximums of 10.1% and
14.9% at the 6-month time point. Whether blood DHA levels
reached a ceiling is not known. In other studies, children with
cystic fibrosis supplemented 6 months with 50 mg DHA/kg/d
had an increase in RBC-DHA levels from 2.8% 6 0.1% to 11.1%
6 0.3% (mean 6 SE); two patients reached an RBC-DHA level
of 13.1%.27 In a 1-year trial, children provided with 100 mg
DHA/kg/d had an average 5-fold elevation in plasma DHA.29
The DHA provided in this trial was high dose compared
with many cardiovascular studies using fish oil.38 However, n3
fatty acids are building blocks of membranes throughout the
body and DHA, specifically, is present in abundance in neural
tissues including the retina, emphasizing importance in this
tissue. The DHAX trial dose was based on bodyweight, thus the
heaviest participant had a daily capsule intake of 18 capsules or
9 g oil/d, which is less than the fat (13 g) in a single doughnut.
However, the DHA provided by this intervention is consider-
ably more than found in the typical, n6-rich Western diet. The
mean daily DHA intake in the US population is
70 mg39 compared with the mean 2200 mg/d DHA supple-
mented in the DHAX trial; furthermore, the average DHAX
dose represents only 2.8% of the typical US daily fat intake (79
g/d).40 Thus, supplementation with DHA should not be
considered a pharmaceutical approach to treating XLRP, but
provision of dietary macronutrients necessary for optimizing
cell membrane structure and function.
Competitive inhibition by DHA resulted in 24% to 28%
reductions of ARA in plasma and RBCs, subsequently
modifying the ARA/DHA baseline ratios from 5.2 to 1.0 in
plasma and 5.8 to 1.2 in RBC by year 4. The ARA/DHA ratio in
the placebo group remained at 5.6 through 4 years. Similarly,
DHA supplementation resulted in 8- to 10-fold differences in
the ratios of end products of n6 and n3 metabolism, namely
DPAn6-to-DHA in plasma and RBCs (Tables 2, 3). Of particular
interest is the 62% lower plasma n6-to-n3 PUFA ratio at year 4
in DHA-supplemented participants compared with placebo
(5.6 vs. 14.8). The typical n6/n3 ratio associated with Western
diets is 16.741; thus, desirable target ratios of 242 and 443 have
been recommended for maintenance of a healthy fatty acid
profile. Reducing the n6/n3 ratio can be achieved by either n3
supplementation or reduction in n6 PUFA intake. Alaskan
Eskimos with a high n3-rich fish intake have plasma PUFA
ratios of 3.5.44 High intake of n3 fatty acids and low
n6/n3 ratios are associated with lower rates of cardiovascular





Group (n ¼ 27)
DHA Group
(n ¼ 33)
Stomach ache/flu/pain 4 6
Dehydration 0 2





Corneal abrasion, due to ERG lens 1 0
Total 6 13
Blood Chemistry TEAEs





Low HDL cholesterol 5 2
Elevated LDL cholesterol 0 2
Elevated total cholesterol 1 2
Elevated SGPT 0 1
Elevated potassium† 4 0
Elevated glucose 3 0
Total 13 7
* Reported by participant noncompliant with trial protocol.
† Clinical lab (LabCorp) considered due to incomplete serum
separation.
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disease and atherosclerosis.41 The American Heart Association
recommends that individuals with coronary artery disease take
at least 1g/d of DHA plus EPA.39
Despite altered blood fatty acid profiles, comprehensive
metabolic analyses revealed no consistent changes of clinical
relevance during the DHAX trial (Table 1). As a tissue with high
oxygen utilization, the retina is susceptible to oxidative
stress13; nevertheless, group differences in antioxidant status
were nonsignificant, but directionally favoring lower oxidative
stress in the DHA group. Total plasma antioxidant activity was
2-fold greater, plasma vitamin A and E levels were marginally
elevated, and oxLDL slightly decreased at year 4 in the DHA-
supplemented group. Studies of DHA supplementation in RP
have failed to demonstrate that DHA acts as a target for free
radical-induced oxidative stress resulting in exacerbation of
disease progression.18–20 In in vitro studies, the double bonds
of DHA are susceptible to oxidation, yet once incorporated
into tissue lipids, DHA appears to possess antioxidative
action.45,46 Supplementation in Rett syndrome (72.9 mg
DHA/kg/d) significantly reduced (P < 0.001) isoprostane-
indexed oxidative stress and lessened disease severity (P ¼
0.02).28,47 In the DHAX trial, daily multivitamin supplementa-
tion as well as DHA may have provided adequate antioxidants
to support the body’s natural defense system against oxidative
stress. Furthermore, the specialty oils derived from algae (such
as DHASCO) are less susceptible to peroxidation than fish oil
fatty acid preparations as determined by rancimat analysis.48
Early n3 fatty acid supplementation studies reported
decreased platelet aggregation resulting in modestly prolonged
bleeding times.15,49 A meta-analysis of eight fish oil supple-
mentation trials (1.72–4.60 g fish oil/d) found no influence to
incidence of major bleeding episodes.38 A literature survey by
Harris50 concluded that ‘‘the risk for clinically significant
bleeding was virtually nonexistent’’ among fish oil supplemen-
tation studies and is similarly echoed in a recent systematic
review.51 Over the 4-year DHAX trial, 30 mg/kg/d DHA
supplementation was without a significant effect on platelet
aggregation (P ¼ 0.80; Table 1); bleeding times were not
measured.
Docosahexaenoic acid supplementation did not significant-
ly alter lipoprotein cholesterol or TG profiles in the DHAX trial,
nor were there alterations in the majority of blood chemistry
metabolites. Although a disruption of glycemic regulation has
been associated with n3 fatty acid treatment,52 mean fasting
glucose levels were marginally reduced after the 4-year DHA
intervention compared with placebo (P ¼ 0.08; Table 1). Fish
oil n3 fatty acid doses of 2 to 4 g/d (750–1500 mg DHA; 930–
1860 mg EPA) are prescribed for patients with hypertriglycer-
idemia.17 For an average 80 kg adult, the 4 g daily dose of n3
fatty acid would equate to approximately 50 mg/kg/d. In
contrast, DHAX trial participants received the long-term dose
of 30 mg/kg/d and averaged 2200 mg DHA/d, yet only
exhibited a modest, nonsignificant reduction in plasma TG
(33 mg/dL compared with placebo; P ¼ 0.10; Table 1).
Similarly, no overall changes in total, LDL-, or HDL-cholesterol
were found in DHAX participants receiving DHA.
A phase I clinical trial using 400 mg/d in XLRP showed that
neither visual function nor biosafety was compromised by
long-term DHA supplementation.21 In a clinical trial providing
1200 mg DHA/d to adult RP patients, no negative effects on
visual function were found.19 In three meta-analyses of fish oil
studies providing up to 4.6 g/d of EPA and DHA to over 5000
subjects, no severe adverse events were documented.17,38,51
Mild GI distress characterized as flatulence, eructation, and
loose stools were reported for a few individuals with a rate not
significantly different from those receiving placebo. The
occurrence of TEAEs in the DHAX trial was consistent with
these safety outcomes.
Docosahexaenoic acid continues to be evaluated and
recommended as treatment and prophylaxis for various disease
states. Since minimal metabolic anomalies and no severe
adverse events occurred in the 4-year DHAX trial, the 30
mg/kg/d DHA dose does not pose a safety risk to the majority
of individuals. Patients deciding to take high doses of DHA
should be monitored closely, particularly those with personal
or family history of GI problems.
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